ARCHIVES

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

NEJM Does About-Face, Issues Correction On CT Lung Cancer Screening Study.

April 4, 2008

Hammer Gives $100,000 to Expand Rosenberg’s T-Cell Growth Factor Clinical Studies

March 1, 1985

NCI-Approved Clinical Trials

April 26, 2002

DePinho’s Letter to CPRIT’s Gimson, And Gimson’s Response

June 1, 2012

OSCC Groups Send Four Concepts To NCI Board

September 13, 1985

Cancer Advocates Seek 6.5% Increase For NCI In Fiscal 1997

March 8, 1996